Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

ording, dial 800-642-1687 (U.S. or Canada) or 706-645- 9291 (internationally) and enter the digital pin number 37155333. An audio replay will also be available approximately two hours after the conference and can be accessed through the Company's website at http://www.entremed.com. EntreMed's fourth quarter update call was held today at 10:00 a.m. ET. A digital recording will be available approximately two hours after completion of the conference and will be accessible for 60 days. To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the digital pin number 37155333. In addition, an audio replay will also be available on the Company's website at http://www.entremed.com approximately one hour after the conclusion of the live conference.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced ... of 15,000,000 shares of its common stock at a ... Dendreon also granted to the underwriters a 30-day option ... common stock to cover overallotments, if any. The ... subject to customary closing conditions. ,, J. P. Morgan ...
(Date:12/10/2009)... (NEI), a division of the National Institutes of Health (NIH), ... fund its development of a non-invasive, passive diffusion-based treatment for ... ... Salt Lake City, UT (PRWEB) December 10, 2009 -- ... Institutes of Health (NIH), awarded a $2.18 million grant to ...
(Date:12/10/2009)... YM BioSciences Inc. (NYSE Amex: YMI ; ... that identifies and advances a diverse portfolio of ... today provided an update on the proposed transaction ... Ltd. into YM, details of which were announced ... of Cytopia has unanimously recommended that its shareholders ...
(Date:12/10/2009)... Dec. 10 Vivakor, Inc. (OTC ... has entered into an exclusive, $5 million ... International, Inc. ( www.regeneca.com ). The ... to a new cutting-edge nutraceutical formulation developed ... of future formulations by Vivakor for Regeneca. ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... the very, very small nanotechnology Americans have a ... of nature, it seems, are failing the moral litmus test ... in the journal Nature Nanotechnology , survey results from ... the perception that nanotechnology is morally acceptable. Those views, according ...
... 5 Yourway Transport,( http://www.yourwaytransport.com ), a premium ... handling needs in the,pharmaceutical, biotechnology and medical/healthcare industries, ... its global customer base. The,expansion includes a new, ... Process. , ...
... BETHESDA, Md., Dec. 5 /PRNewswire-FirstCall/ -- Micromet, ... developing novel, proprietary antibodies for the treatment of cancer, ... and Chief Executive Officer, Dr. Christian Itin, will participate ... Cancer" at the RBC Capital Markets Healthcare Conference on ...
Other Biology Technology:For nano, religion in US dictates a wary view 2For nano, religion in US dictates a wary view 3Yourway Transport Expands 2Micromet to Present at the RBC Capital Markets Healthcare Conference 2Micromet to Present at the RBC Capital Markets Healthcare Conference 3Micromet to Present at the RBC Capital Markets Healthcare Conference 4
(Date:12/13/2009)... led by Yale University researchers has used nanosensors ... the first time. Their findings, which appear December ... Nature Nanotechnology , could dramatically simplify the way ... diseases. , The teamled by Mark ... Applied Science, and Tarek Fahmy, an associate professor ...
(Date:12/11/2009)... Malus orientalis species of wild apples that could be ... Middle East and Central Asia. A new study comparing ... varieties from Georgia and Armenia with previously collected varieties ... and establishes a core collection that will make ... research communities. , To identify and record the genetic ...
(Date:12/11/2009)... Pike, an associate professor of anthropology at the University ... northern Kenya to understand how violence shapes the health ... results of her and her colleagues, research," Documenting the ... of northern Kenya: A conceptual framework," is currently published ... Medicine , in collaboration with the British medical journal ...
Breaking Biology News(10 mins):Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Understanding apples' ancestors 2UA-led study grapples with health effects of low-intensity warfare 2On HIV Testing Day HIVMA calls for health care reform to make testing routine every day 49660 1On HIV Testing Day HIVMA calls for health care reform to make testing routine every day 49660 2VA Secretary Hits the Road to Highlight 22United We Serve 22 Effort 49658 1VA Secretary Hits the Road to Highlight 22United We Serve 22 Effort 49658 2Promising Therapy for Prostate Cancer 49656 1Promising Therapy for Prostate Cancer 49656 2
... smoother and more efficient that exploits the inertia of a ... speed variation, according to research published in the International ... touted as a clean and inexhaustible energy source across the ... output of wind farms can be variable. Proposed measures to ...
... WI, JANUARY 5, 2009 Currently, plant testing ... risks from chemical pesticides to nontarget plants requires ... Protection of the plant development and reproduction are ... of animals. Past research conducted by the USEPA ...
... In 2004 Lyncean Technologies announced the construction of the ... inverse Compton scattering to produce high-intensity, tunable, near-monochromatic x-ray ... protein structure determination to the home laboratorybut it has ... spectrum of x-ray science. , Today, at the ...
Other Biology News:Tilting at wind farms 2First Science from the Compact Light Source: A miniature synchrotron for your home lab 2First Science from the Compact Light Source: A miniature synchrotron for your home lab 3
... This thin foil heat sealing material ... pressure from a screw down heated ... is a useful method for sample ... over the existing seal. Ideal for ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... CHEMICON Re-Blot Plus Western Blot Strong Antibody ... antibodies from Western blots that have been ... other isotopes. It is not recommended for ... as it is not possible to effectively ...
...
Biology Products: